SCHEMBL709134

SCHEMBL709134

Cc1cccc(NC(=O)NCc2ccc(NC(=O)c3ccn4ncnc(N)c34)cc2)c1

nearest known ligand 0.84

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKB Q96GD4 11/20 0.84
AURKA O14965 10/20 0.84
EGFR P00533 2/20 0.66
CDK1 P06493 2/20 0.66
PIM1 P11309 2/20 0.66
MARK3 P27448 2/20 0.66
JAK3 P52333 2/20 0.66
STK3 Q13188 2/20 0.66
ROCK1 Q13464 2/20 0.66
NTRK2 Q16620 2/20 0.66
MARK2 Q7KZI7 2/20 0.66
KDR P35968 2/20 0.66
IKBKB O14920 1/20 0.66
PDPK1 O15530 1/20 0.66
NTRK1 P04629 1/20 0.66
LCK P06239 1/20 0.66
FYN P06241 1/20 0.66
LYN P07948 1/20 0.66
MAPK1 P28482 1/20 0.66
FLT3 P36888 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL707164 0.91 AURKB (1.00) AURKBAURKAEGFRCDK1PIM1
SCHEMBL709079 0.91 AURKB (1.00) AURKBAURKAEGFRCDK1PIM1
SCHEMBL711347 0.90 AURKB (0.88) AURKBAURKAEGFRCDK1PIM1
SCHEMBL710921 0.88 AURKB (0.94) AURKBAURKAEGFRCDK1PIM1
SCHEMBL708691 0.87 AURKB (0.86) AURKBAURKAEGFRCDK1PIM1
SCHEMBL710759 0.86 AURKB (1.00) AURKBAURKAEGFRCDK1PIM1
SCHEMBL708721 0.86 AURKB (0.88) AURKBAURKAEGFRCDK1PIM1
SCHEMBL709069 0.84 AURKB (1.00) AURKBAURKAEGFRCDK1PIM1
SCHEMBL707163 0.83 AURKB (0.84) AURKBAURKAEGFRCDK1PIM1
SCHEMBL708684 0.83 AURKB (1.00) AURKBAURKAEGFRCDK1PIM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8124759-B2 Inhibitors of protein kinases ABBOTT LABORATORIES (US) 2012-02-28 US claimed
US-20090131425-A1 INHIBITORS OF PROTEIN KINASES ABBOTT LABORATORIES (US) 2009-05-21 US claimed
US-8124759-B2 Inhibitors of protein kinases ABBOTT LABORATORIES (US) 2012-02-28 US disclosed
EP-2297151-A1 INHIBITORS OF PROTEIN KINASES Abbott Laboratories (US) 2011-03-23 EP disclosed
WO-2009136966-A1 INHIBITORS OF PROTEIN KINASES ABBOTT LABORATORIES (US) 2009-11-12 WO disclosed
US-20090131425-A1 INHIBITORS OF PROTEIN KINASES ABBOTT LABORATORIES (US) 2009-05-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131425-A1 INHIBITORS OF PROTEIN KINASES AURKC, AURKB, PLK1 AURKB 2/4885AURKA 4/4885EGFR 754/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.